Core Viewpoint - The article discusses the advancements in CAR-T cell therapy for blood cancers and highlights the limitations of this therapy in treating solid tumors, emphasizing the potential of invariant Natural Killer T (iNKT) cells in cancer immunotherapy [3]. Group 1: iNKT Cells and CAR-iNKT Therapy - iNKT cells are a unique subset of T lymphocytes with allogeneic potential and strong homing ability to solid tumors, making them attractive for cancer immunotherapy [3]. - CAR-redirected iNKT (CAR-iNKT) cells have shown promise in anti-tumor applications, but their clinical efficacy is limited by insufficient activation in vivo and poor long-term survival in the tumor microenvironment [3]. Group 2: iMRAS Development - A research team from UCLA developed a biomimetic platform called iMRAS (iNKT cell-targeted Microparticle Recruitment and Activation System) that acts as an in vivo charging station to enhance the therapeutic effects of CAR-iNKT cells [4][6]. - The iMRAS platform consists of alginate microspheres embedded with nanoparticles that release immune-stimulating molecules, designed to recruit and activate CAR-iNKT cells in vivo, promoting their expansion and persistence [6]. Group 3: Mechanism and Impact - iMRAS provides chemotactic and activation signals, including a CD1d-αGC complex to simulate antigen presentation and an IL-15/IL-15Rα complex to enhance CAR-iNKT cell proliferation and longevity [6]. - The study indicates that iMRAS significantly improves the persistence and tumor-suppressive capabilities of CAR-iNKT cells in preclinical models of lymphoma and melanoma [6][8].